Suracell

SuraCell is a South Korean biotechnology company specializing in the development of next-generation cell therapies, with a primary focus on Natural Killer (NK) cell and stem cell technologies. The company's core mission is to provide innovative solutions for cancer treatment and regenerative medicine through its proprietary cell expansion and activation platforms. SuraCell's lead therapeutic candidate, SR-NK-01, is an autologous NK cell therapy currently undergoing clinical evaluation for the treatment of various solid tumors, including lung and liver cancers. Beyond its clinical pipeline, the company offers comprehensive cell banking services for immune and stem cells, ensuring long-term preservation for future therapeutic use. SuraCell also leverages its expertise in cellular biology to develop high-end cosmeceuticals and regenerative products. Operating out of its GMP-certified facilities in Seoul, the company is positioned as a significant player in the growing Asian cell therapy market.